La Rosa Holdings names Nicholas Adler chairman of the board

La Rosa Holdings Corp. (NASDAQ: LRHC) appointed Nicholas Adler as a member of its board of directors, effective December 29, 2025. Adler was simultaneously named chairman of the board, chairman of the compensation committee, and a member of both the audit committee and the nominating and corporate governance committee.

The appointment follows the resignation of Siamack Alavi from the board on December 29, 2025. Alavi also stepped down from his roles as chairman of the compensation committee and as a member of the audit committee and the nominating and corporate governance committee. The company stated that Alavi's resignation did not result from any disagreement with the company on matters relating to its operations, policies, or practices.

Adler is a licensed attorney who has served as a partner at Brock & Scott PLLC since 2012, specializing in defense litigation, bankruptcy, foreclosure, and real estate matters. He previously practiced securities regulation with an international law firm in New York. Since 2005, his work has focused on representing national and regional credit grantors in Tennessee.

Adler is also active in real estate development and asset management through Q&A Developments, LLC, where he serves as a principal focused on multi-family and mixed-use projects. He currently serves as chairman of the board of Freight Technologies, Inc. (NASDAQ: FRGT) and, since November 2025, as a director of Aero Velocity Inc., a drone technology company. He earned his B.A. in Political Science from Vanderbilt University and his J.D. from The Washington and Lee University School of Law.

La Rosa Holdings is a real estate and PropTech company that operates 25 corporate-owned brokerage offices across Florida, California, Texas, Georgia, North Carolina, and Puerto Rico, with expansion into Spain. The company also has five franchised offices and branches and three affiliated brokerage locations in the U.S. and Puerto Rico.

You May Also Be Interested In

• Valion Bio names CFO Lisa Wolf as president and COO after CEO exits
• Intelligent Bio Solutions raises $5M in private placement
• Daxor reports 16% kit sales growth in first half of 2026